CSO Phil Stephens said the firm is finding specific genomic alterations that appear to affect sensitivity to immunotherapies, as it also advances overall mutation burden testing.
A series of new studies contain clues to predicting heart disease in healthy individuals and future problems in those already treated for cardiovascular conditions.
